Heart Failure

High-level results show the trial met its composite primary endpoint, lowering risk of CV death or worsening disease in patients with HFmrEF/HFpEF.

PCPs and internists accounted nationally for 57% of SGLT2i and 52% of GLP1RA prescriptions in 2020, more than any other specialty, according to new research.

The cardiac myosin inhibitor is the only treatment that targets the pathophysiology of the disease, improving patient function and symptoms.

Persons with ASCVD who quit smoking could gain 5 more years of life--similar to the outcome of intensive medical treatment while continuing to smoke.

In patients with type 2 diabetes and chronic kidney disease with and without history of CVD, finerenone was associated with improved CV and kidney outcomes.

The new HF guidelines prioritize primary prevention, revise disease stages to encourage early intervention, and now include SGLT2i as guideline-directed medical therapy.

ACC 2022. An EHR alert tailored to prompt clinicians to check guideline-directed medical therapy for individual HF patients was integrated carefully into clinical workflow.

ACC 2022. SODIUM-HF secondary findings, however, showed improvement in NYHA HF class and in QOL in the dietary intervention group.

ACC.22: Findings from 3 studies show drinking 2-3 cups of coffee per day is associated with a reduced risk of CVD, abnormal heart rhythms, and mortality.

The landmark approval for the SGLT-2 inhibitor will open access to treatment for the ~ 3 million adults with heart failure with preserved ejection fraction.

Finerenone, the nonsteroidal mineralocorticoid receptor antagonist, significantly reduced new-onset HF and improved other HF outcomes in the FIGARO-DKD trial.

Increases in obesity parameters significantly increased risk of incident heart failure in persons with diabetes, but not without diabetes, in a large community-based cohort study.

Treatment with aspirin of patients with cardiovascular risk factors was consistently associated with a greater than 25% risk of incident HF, another strike against the OTC antithrombotic.

Smoking was associated with earlier onset of cardiovascular disease, by 5.1 years for men and 3.8 years for women, the new study found.

AHA 2021. Heart failure patients, across ejection fraction and diabetes status, reported improved QOL as early as 3 months in CHIEF-HF trial.

AHA Scientific Sessions 2021: New research provides a note of caution for the use of digital heart failure coaching apps in severely ill and elderly patients with unstable heart failure.

Heart failure drugs in the pipeline now number more than 100 and include familiar names plus dozens of new ones. Get a top-line look at 6 of the most promising.

Results of a GALACTIC-HF post-hoc analysis suggest a role for omecamtiv mecarbil in an HF population that remains difficult to treat effectively.

Advances in heart failure management, including inroads in treatment for HFpEF, are happening fast. Try 8 questions to find out how well you’ve been following the news.

A survey of adults aged 50-80 years with hypertension and/ or related comorbidities found even among those with a BP monitor at home, less than 50% checked BP at least once a week.

SGLT-2 inhibitors have proven effective in disease modification as well as symptom improvement across HF phenotypes and severity. Get a quick summary of the research.

Iron deficiency can't be causally linked to CHD yet, but evidence is accumulating for the association, according to authors of a new European study.

EASD 2021: Patients with metabolically healthy obesity are nearly 33% more likely to develop heart failure and atrial fibrillation than healthy persons of normal weight, suggests new analysis.

Clinical decisions on LDL-C management currently rely on a measure at one time point, typically middle age. A new study suggests burden begins early and so should assessment.

Dapagliflozin adds substantial improvements in symptoms, exercise function to demonstrated disease-modifying properties for patients with HFpEF.

In a pooled analysis of 2 key clinical trials, empagliflozin was beneficial in patients with heart failure with a reduced and preserved ejection fraction.

Empagliflozin in patients with HFpEF reduced by 21% the risk of cardiovascular death or heart failure hospitalization across all prespecified subgroups, including those with/without diabetes.

The ESC Congress 2021, Aug 27-30, 2021, is here. For primary care, we highlight the "Hot Lines" clinical trial presentations where new data from novel trials will premier.

The new indication for empagliflozin is to reduce risk of CV death and hospitalization for heart failure in patients with HFrEF,

Delaying or forfeiting care for HF significantly increased future health care costs, a finding at odds, say study authors, with the inability to afford regular treatment.